The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic total Nasal Polyp Score) and change from baseline in bi-weekly mean nasal congestion (measured by ...
Vice Chair of Rhinology & Endoscopic Sinus and Skull Base Surgery, and Allergy, Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School, US, and co-primary investigator in the trial, ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
2,3 "Chronic rhinosinusitis with nasal polyps negatively impact patients' daily lives with the obstructions leading to ...
A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
1 The co-primary endpoints of the trial, were change from baseline in total nasal polyp size, measured by the endoscopic ...
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback